Showing 891-900 of 7665 results for "".
- Blocking LSD1 May Thwart Common Skin Cancer Growthhttps://practicaldermatology.com/news/blocking-lsd1-may-thwart-common-skin-cancer-growth/2460130/The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow. A new study from researchers in the Perelman School of Medicine at the University of Pennsylvania has now identified a key regulator of that block known as LSD1, as wel…
- Why Don't More Derms Use Lab-based Tools to ID Fungal Infections?https://practicaldermatology.com/news/why-dont-more-derms-use-lab-based-tools-to-id-fungal-infections/2460128/Fungal diagnostic preparations can assist the accurate diagnosis of cutaneous fungal infections. A survey from a team at the George Washington University (GW) identifies barriers that prevent their consistent use. The study is published in the Journal of Drugs in Dermatology. With cutaneous fungal…
- Scaravoid May Offer A New Approach to Wound Healinghttps://practicaldermatology.com/news/scaravoid-may-offer-a-new-approach-to-wound-healing/2460126/A new foam that is placed in skin wounds to support and optimize the natural healing process may help prevent scarring. With the "Scaravoid" project, Markus Rottmar, PhD and his team at Empa's Biointerfaces lab in Switzerland are now intervening at several stages in the process to improve wound he…
- Mode of Delivery at Birth May Shape Child's Skin Microbiomehttps://practicaldermatology.com/news/mode-of-delivery-at-birth-may-shape-childs-skin-microbiome/2460123/New research shows that bacterial genera in children were more similar to those of their own mothers than to those of unrelated women. Their data suggest that the mode of delivery at birth could be an important factor in shaping the child's microbiome. The findings appear in the Journal of Investi…
- Foamix Submits NDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosaceahttps://practicaldermatology.com/news/foamix-submits-nda-for-fmx103-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea/2460117/Foamix Pharmaceuticals Ltd. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for FMX103 for the treatment of moderate-to-severe papulopustular rosacea in patients 18 years of age and older. “It can be challenging for patients with papulopu…
- Has Cellulite Finally Met its Match with BTL’s Emtone?https://practicaldermatology.com/news/has-cellulite-finally-met-its-match-with-btls-emtone/2460114/Drumroll please…BTL is launching Emtone, a device that targets cellulite via thermal monopolar radiofrequency and mechanical targeted pressure energy simultaneously. This combination results in increased production of collagen and elastin to effectively address all major contributing factors to ce…
- Vitamin A May Lower SCC Riskhttps://practicaldermatology.com/news/vitamin-a-may-lower-scc-risk/2460113/Higher vitamin A intake may reduce risk for cutaneous squamous cell carcinoma, a new study shows. Researchers culled data from two long-term study groups including nearly 125,000 health professionals in the U.S. to see if intake of vitamin A, through diet and supplementation, affects risk of cutan…
- Modernizing Medicine: New Capabilities Address Price Transparency, Patient Engagementhttps://practicaldermatology.com/news/modernizing-medicine-new-capabilities-address-price-transparency-patient-engagement/2460100/Modernizing Medicine® will showcase new and enhanced capabilities for price transparency, digital patient engagement and more to the company’s electronic health records (EHR) platform, EMA®, and Practice Management system at the American Academy of Dermatology (AAD) 2019 Summer Meeting this week in…
- Revance Adds New Member to Board of Directorshttps://practicaldermatology.com/news/revance-adds-new-member-to-board-of-directors/2460096/Chris Nolet is the newest member of Revance Therapeutics, Inc.’s Board of Directors. He will serve as the Chair of the Revance Audit Committee. “Chris Nolet brings an extraordinary record of industry-shaping consultation to the Revance Board of Directors,” says Dan Browne, President and Chief Exec…
- Novartis Offers Free Genetic Testing for Advanced Melanomahttps://practicaldermatology.com/news/novartis-offers-free-genetic-testing-for-advanced-melanoma/2460095/The Know Now Testing Program is an initiative from Novartis in collaboration with Quest Diagnostics that offers genetic mutation testing at no cost for all patients with stage III or stage IV melanoma. Nearly half of all advanced melanoma patients carry a specific mutation, called BRAF. BRAF statu…